- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04293510
Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus
Evaluation of Janus Kinase_3 Expression in Juvenile Onset Systemic Lupus Erythematosus
One of the best understood mechanisms by which cytokines activate signals, thus eliciting specific responses in target cells, involves enzymes such as Janus kinases (JAKs) and transcriptional factors such as signal transducers and activators of transcription (STATs). For immune mediated diseases, both activating and inactivating mutations of JAKs and STATs may cause abnormalities in immune homeostasis. Polymorphisms of JAK/STAT genes have been linked to susceptibility for rheumatoid arthritis (RA) , systemic lupus erythematosus (SLE), psoriatic arthritis (PA) and inflammatory bowel disease (IBD) .
Janus_kinase 3 expression will be evaluated in the serum and renal tissue of lupus patients during active stage of the disease through this study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Enas Mohamed Sayed Ahmed
- Phone Number: 01004870406
- Email: enasmhmd05@gmail.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Age younger than 16 years.
- Active disease stage
- Patients with biopsy proven lupus nephritis according to ISN/RPS classification criteria of lupus nephritis
Exclusion Criteria:
Lupus patients in remission.
- Lupus patients with end stage renal disease.
- Lupus patients with secondary thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS).
- patients with moderate or severe infection
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
group study 1
children and adolescents who diagnosed as lupus patients
|
renal biopsy and blood sampling will be taken from lupus patients for evaluation of Janus-kinase 3
|
group study 2
age and sex matched healthy children free from any infection with no family history of immunological diseases
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Janus-kinase 3 expression
Time Frame: within 2 years
|
evaluation of Janus-kinase 3 expression in blood and renal tissue of lupus patients during active stage of disease
|
within 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
correlation
Time Frame: 2 years
|
relationship between Janus- kinase expression and clinical and laboratory parameters of disease activity
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
correlation
Time Frame: 2 years
|
relationship between Janus-kinase 3 expression and histopathological classification of renal biopsy in lupus nephritis proven patients
|
2 years
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Yamaoka K, Saharinen P, Pesu M, Holt VE 3rd, Silvennoinen O, O'Shea JJ. The Janus kinases (Jaks). Genome Biol. 2004;5(12):253. doi: 10.1186/gb-2004-5-12-253. Epub 2004 Nov 30.
- Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, de Bakker PI, Le JM, Lee HS, Batliwalla F, Li W, Masters SL, Booty MG, Carulli JP, Padyukov L, Alfredsson L, Klareskog L, Chen WV, Amos CI, Criswell LA, Seldin MF, Kastner DL, Gregersen PK. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007 Sep 6;357(10):977-86. doi: 10.1056/NEJMoa073003.
- Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004 Feb;15(2):241-50. doi: 10.1097/01.asn.0000108969.21691.5d. Erratum In: J Am Soc Nephrol. 2004 Mar;15(3):835-6.
- Petri M. Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am. 2005 May;31(2):245-54, vi. doi: 10.1016/j.rdc.2005.01.009.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- EKNL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on renal biopsy and blood sampling
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Institut Paoli-CalmettesCancer Research Center of MarseilleUnknownNeoplasm MetastasisFrance
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingHistiocytosis, Langerhans-Cell
-
University Hospital, GrenobleTerminatedPsychiatric Adults PatientsFrance
-
University Children's Hospital, ZurichUniversity Hospital, Geneva; University Children's Hospital BaselRecruitingImmunologic Deficiency SyndromesSwitzerland
-
Chinese University of Hong KongRecruiting
-
Institut Paoli-CalmettesNovartis PharmaceuticalsRecruitingAdvanced or Metastatic Breast Cancer (BC)France
-
University Hospital, LilleRecruitingSystemic SclerosisFrance
-
Central Hospital, Nancy, FranceRecruitingInflammatory Bowel Diseases | Ulcerative ColitisFrance
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingEpithelial Ovarian Cancer | OrganoidsItaly